Genmab A/S - American Depositary Shares (GMAB) closed at $43.79 on October 23, 2026, up 9.5% from the previous close, on volume of 11,149,904 shares (30-day average 3,623,406).
Data as of October 23, 2026.
23-Oct-2026
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Business Wire (Sat, 24-Oct 7:01 AM ET)
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Business Wire (Sat, 24-Oct 7:00 AM ET)
Genmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancer
Seeking Alpha News (Fri, 23-Oct 3:27 PM ET)
TipRanks (Fri, 23-Oct 1:10 PM ET)
Genmab’s Rina-S Delivers Breakthrough Phase 3 Results in Platinum-Resistant Ovarian Cancer
TipRanks (Fri, 23-Oct 12:18 PM ET)
Globe Newswire (Fri, 23-Oct 11:55 AM ET)
Genmab A/S (0MGB) Receives a Buy from Barclays
TipRanks (Tue, 20-Oct 2:55 AM ET)
Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2026
Globe Newswire (Tue, 13-Oct 6:22 AM ET)
PRNewswire (Mon, 5-Oct 2:55 PM ET)
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Genmab A/S - American Depositary Shares trades on the NASDAQ stock market under the symbol GMAB.
As of October 23, 2026, GMAB stock price climbed to $43.79 with 11,149,904 million shares trading.
GMAB has a beta of 0.75, meaning it tends to be less sensitive to market movements. GMAB has a correlation of 0.08 to the broad based SPY ETF.
GMAB has a market cap of $27.33 billion. This is considered a Large Cap stock.
Last quarter Genmab A/S - American Depositary Shares reported $1 billion in Revenue and $4.91 earnings per share. This fell short of revenue expectation by $-5 billion and exceeded earnings estimates by $4.60.
In the last 3 years, GMAB traded as high as $44.34 and as low as $17.24.
The top ETF exchange traded funds that GMAB belongs to (by Net Assets): IBB, FBT, AVDE, CANC, FTQI.
GMAB has outperformed the market in the last year with a price return of +46.6% while the SPY ETF gained +14.3%. GMAB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +50.1% and +18.1%, respectively, while the SPY returned +3.2% and -2.4%, respectively.
GMAB support price is $39.11 and resistance is $40.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GMAB shares will trade within this expected range on the day.
